anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study is being conducted because there has not been any proper studies to provide evidence that these commonly used "blood activating" herbal preparations can in fact affect blood clotting by interfering with platelet function or clotting mechanism and potentiate the antiplatelet activity of Aspirin. These are assumptions based on TCM theory, laboratory experiments and animal studies but have led to the general statement in medical literature that these herbs increases bleeding risk in patients taking Aspirin or any other anti-platelet drugs. This has resulted in advice that these herbal products should not be taken by patients on Aspirin, which is a common drug taken by many patients. We hope to prove or disprove this theoretical concern by measurement of platelet and clotting function in healthy volunteers before and after taking the herbal product, alone and in combination with Aspirin. This will help to answer the question of whether it is safe for patients to take these common "blood -activating " herbs alone or together with Aspirin.

Healthy volunteers will be consecutively enrolled into 3 arms, each studying one herbal product for 25 volunteers. The design involves taking all 3 of the following combinations: aspirin + placebo, herb + placebo, aspirin + herb, each for a 3-week period, in a randomized order, with 2 weeks of wash-out in between each 3-week period. Platelet function and coagulation profile will be assayed
Anemia continues to be a major public health problem among may age groups, considerably more prevalent in developing countries. Iron deficiency anemia (IDA) occurs when iron deficiency is sufficiently severe to reduce eryththropoiesis, the most frequent chronic anemia. In adults, iron deficiency is commonly associated with poor erythrocyte production, consequently amounting to anemia, significant gastrointestinal tract abnormalities, and may develop epithelial changes like angular stomatitis and glossitis with painful swelling of the tongue. Hence, we had formulated a unique combination, comprising a novel iron preparation, Iron Polymaltose Complex (IPC) with Folic Acid and Ascorbic Acid that we believe shall greatly do well to patients. IPC in some clinical studies showed equal bioavailability as ferrous sulfate and showed more tolerable side effects. Ascorbic acid, in this preparation, will increase the utilization of IPC during the treatment of anemia. Incorporating Folic Acid in the preparation also addresses another common micronutrient deficiency which falls second to iron.
<P>PROBLEM TO BE SOLVED: To provide a sealing and filling composition for filling and/or sealing root canals.  <P>SOLUTION: The sealing and filling composition comprises a polymerizable material undergoing shrinkage when polymerized. The composition comprises a gas releasing component for at least partially offsetting the shrinkage caused by polymerization of the polymerizable material. The gas releasing component offsets the polymerization shrinkage by forming ultrafine gas bubbles causing the expansion in the polymeric material. The gas releasing component may be an acid and a base such as citric acid and sodium bicarbonate providing carbon dioxide when mixed. The composition may contain a dispersing agent for dispersing the gas bubbles in the whole composition.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Standard NAC comprised 2 cycles. Platinum plus paclitaxel or docetaxel was repeated once every 3 weeks. Cis-platinum was administered at a total dose of 75 mg/m2 by continuous infusion on d1 or equal divided on Days 2-4 or Days 1-3. Paclitaxel, 175 mg/m2, d1, or paclitaxel, 87.5 mg/m2, d1, d8. If the docetaxel was adopted, it was given as 75 mg/m2 on Day 1. Then surgery----esophagectomy and two-field extensive mediastinal lymphadenectomy. After surgery, there might be a adjuvant chemotherayp for pathologically positive lymph nodes patients.
OBJECTIVES: This study investigates the mediating roles of autonomic function and mental health in the association between sleep and cognitive decline in adults aged 50 and above.
METHOD: A total of 2,697 participants with observations on sleep and mediators at baseline and repeated measures of cognitive function (MMSE) were included. Clusters of individuals with similar cognitive trajectories (high-stable, mid-stable and low-declining) were identified. Multinomial logistic regressions were used to estimate the likelihood of membership to each trajectory group based on sleep duration and disturbance. Finally, mediation analysis tested potential mediating effects of autonomic function and mental health underpinning the sleep-cognition relationship.
RESULTS: Short (p = .028), long (p =.019), and disturbed sleep (p =.008) increased the likelihood of a low-declining cognitive trajectory. Mental health measures fully attenuated relationships between cognitive decline and short or disturbed sleep but not long sleep. No autonomic function mediation was observed.
CONCLUSION: Older adults with short or disturbed sleep are at risk of cognitive decline due to poor mental health. Individuals with long sleep are also at risk, however, the acting pathways remain to be identified. These outcomes have clinical implications, potentially identifying intervention strategies targeting mental health and sleep as prophylactic measures against dementia.
Patients receiving 1LPEG who had a colonoscopy in the morning were advised to follow a day-before dosing regimen, where, at 7:00 pm the day before the colonoscopy, they prepared the Dose 1 sachet in 500 mL of water and consumed it over a period of 30 minutes, followed by 500 mL of clear liquids. The second dose was then taken at 11:00 pm by mixing the two Dose 2 sachets in a single glass of 500 mL of water and consuming them over 30 minutes, followed by 500 mL of clear liquids. If the colonoscopy was scheduled for the afternoon, the same dosing instructions were given, but the first dose was taken at 7:00 am on the day of the procedure, and the second dose began at 10:00 am.
BACKGROUND/AIM: Vancomycin-resistant Enterococcus causes significant morbidity, mortality, and excess healthcare costs when compared to vancomycin-susceptible isolates. Patients with hematological malignancies, especially those who undergo hematopoietic stem cell transplantation, are at a particularly high risk for infections with vancomycin-resistant Enterococcus, with mortality ranging from 40-100%. Linezolid and daptomycin are the two most commonly used antibiotics for treatment of vancomycin-resistant enterococcal infections, however, there has been recent emergence of resistance to these drugs as well.
CASE REPORT: We report the case of a 48-year-old male with hematological malignancy and graft failure post hematopoietic stem cell transplantation complicated by dialysis-dependent acute kidney injury and recurrent neutropenic fevers due to vancomycin-resistant Enterococcus faecium (VREf) bacteremia. Despite central line changes, and strict aseptic precautions, the bacteremia returned, showing resistance to daptomycin and linezolid after the second recurrence. As a final effort, using limited clinical data and in vitro studies, we utilized oritavancin off-label as salvage therapy for refractory VREf bacteremia, with subsequent clearance of blood cultures.
CONCLUSION: This is a rare case of successful off-label use of oritavancin for recurrent multidrug-resistant VREf bacteremia in a patient with hematological malignancy after undergoing hematopoietic stem cell transplantation. It is important to increase awareness of the potential use of this novel antibiotic with increasing resistance of VREf to first-line agents.
The invention provides methods of expanding BFU-E cells comprising contacting one or more BFU-E cells with a hypoxia inducible factor 1 activator and a glucocorticoid receptor (GR) activator, e.g., a GR agonist. In some embodiments, the FIIF-1 activator is a prolyl hydroxylase inhibitor (PHI). In some embodiments, the method comprises culturing BFU-E in medium containing a HIF-la activator and a glucocorticoid receptor (GR) activator, e.g., a GR agonist. In some embodiments the BFU-E cells are human cells. The invention provides cell culture media useful for expanding BFU-Es, wherein the cell culture media comprise a HIF-1 activator and a GR activator (e.g., a GR agonist) The invention provides a method comprises administering a HIF-1 activator and a GR agonist to a subject in need thereof. In some embodiments, the subject suffers from anemia. In some embodiments, the anemia is an Epo-resistant anemia. In some embodiments, the anemia is Diamond-Blackfan anemia.
The present invention discloses an application of a β3 adrenergic receptor (ADRB3) as a marker for detecting a plurality of diseases, and an application of anti-human ADRB3 monoclonal antibody in diagnosing a disease and preparing a drug for treating the disease. The present invention finds through research that the ADRB3 is a key receptor in nerve-endocrine-immunoregulatory network, and an ADRB3-mediated signaling pathway regulates proliferation and differentiation of neutrophils, lymphocytes and tumor cells. Under normal circumstances, the ADRB3 maintains the non-specific immunocompetence and specific immunocompetence of an organism, and eliminates pathogenic microorganisms and aged organism tissues to play a role in protecting the organism and anti-aging. Under pathological conditions, excessive activation of the signaling pathway will cause systemic chronic inflammation, and destroy immune homeostasis. Therefore, the ADRB3 can be used as a diagnostic marker and a therapeutic target for a plurality of diseases. Anti-human ADRB3 antibody can specifically bond with the ADRB3, regulate the activity of the ADRB3, has the functions of resisting cancer, inflammation, poisoning, shock, allergy, viral infection, autoimmune disease, disease caused by regenerative dysfunction, autoimmune disease, cachexia, cardiovascular and cerebrovascular disease, neurodegenerative disease and aging, regulating autophagy, treating aging disease, etc., and has important medical value and research and application prospects.
The HIPPER group will receive 12 interactive online modules (\~20 minutes each). HIPPER participants will receive email or phone contact (participant preference) to provide them with website portal access consisting of the web address, and simple instructions to access the website using personalized encrypted login information to the site.
The invention discloses a compound traditional Chinese medicine composition for preventing and treating newcastle disease and its preparation method and use, and belongs to the technical field of veterinary traditional Chinese medicines. The compound traditional Chinese medicine composition comprises, by weight, 10-30 parts of radix astragali, 10-25 parts of herba houttuyniae, 10-30 parts of fructus forsythiae, 10-25 parts of common andrographis herb, 5-10 parts of pilose asiabell root, 5-10 parts of plantain herb, 5-10 parts of Chinese angelica, 5-10 parts of fiveleaf gynostemma herb and 5-10 parts of coptis root. Through use of the above nine pure natural traditional Chinese medicines, active ingredients of the pure natural traditional Chinese medicines can be directly used for resisting viruses and can stimulate or improve body specific or non-specific immunization functions so that substantial curative effects of preventing and treating newcastle disease are obtained. Through combination with cordyceps polysaccharide, the compound traditional Chinese medicine composition can substantially improve body immunity, improve effects of preventing and treating newcastle disease and promote chicken growth. Through use of an ultramicro-crushing method, drug bioavailability can be substantially improved. The preparation method has simple processes, can be operated easily and is suitable for large-scale production and application.
While research on substance using youth experiencing homelessness (YEH) is increasing, there is a dearth of information regarding effective prevention interventions for these youth. This is of significant concern because studies indicate that 66% to 89% of YEH have a mental health disorder and 68% report at least one suicide attempt . In fact, suicide is the leading cause of death among YEH. Among those who have attempted suicide, an average of 6.2 attempts is reported, and lifetime suicidal ideation rates range from 14% to 66.5% with no clear evidence of effective interventions for YEH. This study uses general cognitive theory, complemented with concepts from two suicide specific theoretical models, to guide our intervention and conceptual change model. The study goal is to test strategies to extend delivery and uptake of a cognitive therapy intervention for YEH. Prior studies focus on service-connected youth, but research suggests that most street living YEH do not access services meant to assist them. Prior sampling limitations are overcome through engaging service-disconnected youth in addition to service-connected youth through a local drop-in center. As such, three hundred substance using YEH with recent suicidal ideation or a recent suicide attempt will be randomly assigned to Cognitive Therapy for Suicide Prevention (CTSP) + Services as Usual (SAU) (N=150) or to SAU alone (N=150). CTSP has previously shown efficacy for YEH through a RCT pilot feasibility study. SAU includes outreach, advocacy and service linkage which are typical services offered by agencies serving those experiencing homelessness. Follow-up assessments will be conducted at 3, 6, 9 and 12-months post-baseline. It is hypothesized that youth receiving CTSP+SAU will show greater reductions in suicidal ideation (primary outcome), substance use and depressive symptoms (secondary outcomes) over time compared to SAU alone, as well as improved risk and protective factors. Theoretically-derived mediators will be tested to shed light on mechanisms associated with change, and the moderating effects of sex, race, sexual orientation and baseline service connection will be examined. In order to ease future dissemination of the intervention to agencies serving YEH, the investigators will rigorously assess acceptability, feasibility, fidelity and cost associated with the delivery of our intervention approach using a mixed-methods approach. Ultimately, the goal of this research is to provide support for the use of a suicide prevention intervention for substance using YEH that reduces premature mortality, hospitalization, and loss of human capital and which can be easily adopted by agencies serving YEH.
Daily remote ischemic conditioning for 10 days. Remote ischemic conditioning is induced by placing a blood pressure cuff around the right or left arm. The cuff is inflated to 200 mmHg and the pressure is kept for 5 minutes. Hereafter the cuff is deflated for 5 minutes completing one cyclus. This cyclus is repeated 4 times.
Participants received 3 cycles of cisplatin 75 mg/m\^2 with pemetrexed 500 mg/m\^2 and pembrolizumab 200 mg on Day 1 of each cycle. Treatment was given in conjunction with standard TRT (60 Gy in 2 Gy fractions administered 5 days per week for 6 weeks) in cycles 2 and 3. Participants then received 14 additional cycles of pembrolizumab 200 mg administered Q3W. 1 cycle=21 days.
The invention provides methods of detecting transthyretin (TTR) using a capture antibody and a reporter antibody. The capture antibody binds preferentially to misfolded TTR over native tetrameric form of TTR. The capture antibody binds to an epitope within amino acid residues 89-97 or TTR or to an epitope within amino acid residues 101-109 of TTR. 9D5 and 18C5 are examples of suitable capture antibodies. The methods can be used for diagnosing diseases or disorders associated with TTR accumulation or accumulation of TTR deposits ( e.g. , TTR amyloidosis) and for monitoring the efficacy of TTR therapies, among other applications.
PURPOSE:To produce human interferon in high productivity, by contacting whole blood with an anticoagulant and virus, and incubating in a vessel. CONSTITUTION:Collected blood or the whole blood obtained by removing the liquid plasma from the blood and suspending the resultant whole solid components in other liquid (e.g. physiological saline water, nutrient medium, etc.) is incubated (e.g. at 30-40 deg.C for 5-50hr) in a vessel in the presence of an anticoagulant such as heparin, ACD, etc. and virus, to produce interferon. The virus is preferably an inactivated virus e.g. Sendai virus, Newcastle disease virus or their inactivated virus and having th hemagglutination value of 20-200,000 HA per 1ml of the whole blood.
PROBLEM TO BE SOLVED: To obtain an adhesion mixture for tightly fixing a dental filling material to a dentine and an enamel. SOLUTION: This method for fixing a dental filling material having bond strength comprises using a mixture composed of (i) 10-90 pts.wt. of at least one single or repeated ethylenically unsaturated phosphoric ester, (ii) 5-85 pts.wt. of a solvent, (iii) 0.01-5 pts.wt. of an initiator capable of forming a free radical and (iv) 0-10 pts.wt. of an ordinary auxiliary and additive. Immediately after the mixture is applied to a hard tooth substance, coating is carried out by using a polymerizable filling material. When the mixture is applied to a hard tooth material in a certain process and immediately the polymerizable filling material is applied without using another aftertreatment different from a conventional method, a merit of obtaining adhesion bond equal to that of a conventional case is obtained.
The invention discloses Lachnum sp. YM-281, an extracellular polysaccharide thereof and application of the extracellular polysaccharide in preparing lipid-lowering liver-favoring medicaments. The invention is characterized in that a Lachnum sp. YM-281 strain with the collection number of CCTCC (China Center for Type Culture Collection) No: M 2011196 is activated and inoculated to a fermentation culture medium, thus preparing the Lachnum sp. YM-281 extracellular polysaccharide. When the administration dosage is 150-300 mg/(kg bw), the prepared Lachnum sp. YM-281 extracellular polysaccharide can significantly lower the levels of serum lipid and liver lipid and atherosis index of high-lipid mice, and increase the level of serum high-density lipoprotein cholesterol and the excretion amount of feces lipid. When the administration dosage is 75-300 mg/(kg bw), the prepared Lachnum sp. YM-281 extracellular polysaccharide can significantly lower the activity of serum aminotransferase and malondialdehyde content in liver tissues of high-lipid mice, and increase the activity of sudismase in the liver tissues. The prepared Lachnum sp. YM-281 extracellular polysaccharide has obvious effects of lowering blood lipid, lowering liver lipid, and treating hepatic injury and dysfunction caused by high lipid, has no toxic or side effects, and can be prepared into tablets or capsules for clinical application.
Cardiovascular disease is the leading cause of mortality worldwide. Risk factors associated with cardiovascular disease including obesity, blood pressure and blood lipids have been shown to track from childhood through to adulthood. The prevalence of overweight and obesity for children (4-18 years) in the UK is reported to be 15 % and 4 % respectively. Furthermore, in comparison to England (2.9 %) obesity is more prevalent for those living in Scotland (7.6 %) and Wales (6.5 %). Previous research from two Welsh secondary schools indicate overweight and obesity rates for boys and girls aged 12-13 to be even greater at 26 % and 38 % respectively. Further to this, 19 % were identified as having elevated total cholesterol (≥5.2 mmol/L).

For many, overweight and obesity is the result of the combined effect of excess energy consumption and inadequate physical activity. Previous school-based physical activity interventions have demonstrated modest improvements to cardiovascular disease risk factors by implementing extra-curricular activities or improving current physical education curriculum. Few have attempted to increase physical activity using normally, class-room taught curriculum subjects. This study examines the impact of activity knowledge circuits to combat cardiovascular disease risk factors in 11-14 year old children.
This is a non-blinded study in subjects who present to the UCSF Memory and Aging Clinic (MAC) with neurodegenerative disease and cognitive dysfunction. The primary objective of this non-significant risk study is signature development. The goal is to develop a signal algorithm using the Nautilus NeuroWaveTM for dementia. This is accomplished by analyzing and processing Nautilus NeuroWave recordings from a patient with confirmed dementia. All subjects will be enrolled until recordings are obtained from at least 10 of each of the following subject cohorts: Moderate or Severe Frontotemporal Lobar Degeneration (FTDL), Alzheimer's Disease, Mild Cognitive Impairment (MCI) and Age Matched Normal Controls.

As this study is a feasibility study intended to determine whether the Nautilus NeuroWave is able to generate distinctive signals correlated with dementia, statistical analysis will not be required. Similarly, the study has not been powered to attain any particular level of statistical significance. Subsequent studies will measure sensitivity and specificity of any resulting dementia signal pattern generated by this study. These future studies will be subject to statistical analysis.

The Jan Medical Nautilus NeuroWaveTM (NNW) is a non-invasive device designed to evaluate brain oscillation patterns or the brain's pulse, generated by cardiac cycle induced intracranial blood flow. The objective of the evaluation is to determine whether the oscillation pattern is normal, whether it has been disrupted, and, if disrupted, what particular disruption pattern is evident. Various cerebral pathologies studied to date with the NNW demonstrate distinct disruption patterns. These pathologies include vasospasm, concussion and arterio-venous malformation (AVM). The objective of this study is to evaluate the brain oscillation patterns from subjects with MCI, Frontotemporal dementia, AD and from a small cohort of age matched normal controls and determine whether they exhibit pattern disruption and, if so, to quantify and categorize the distinct disruption patterns. How the Nautilus NeuroWave accomplishes this is explained later in the device description section of the protocol.
Cognitive impairment and dementia are common in patients with chronic kidney disease, including those undergoing hemodialysis. Since magnesium and phosphate play important roles in brain function and aging, alterations in these and other factors related to bone mineral disorder (MBD) may contribute to low cognitive performance in patients on hemodialysis. This cross-sectional study examined the associations between cognitive function and MBD-related factors among 1207 patients on maintenance hemodialysis. Cognitive function was assessed by the Modified Mini-Mental State examination (3MS). The exposure variables of interest were serum magnesium, phosphate, calcium, calcium-phosphate product, intact parathyroid hormone, fetuin-A, T50 calciprotein crystallization test, use of phosphate binders, use of cinacalcet, and use of vitamin D receptor activators. Multivariable-adjusted linear regression models were used to examine the associations between 3MS and each of the exposure variables independent of 13 potential non-mineral confounders. We found that lower 3MS was associated with lower serum magnesium, lower phosphate, lower calcium-phosphate product, and nonuse of phosphate binders. These results suggest that magnesium and phosphate play potentially protective roles against cognitive impairment in this population.